MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin

Melanoma Research

Volumn 25, Issue 2, 2015, Pages 113-118

  Bønnelykke Behrndtz, Marie L ^a   Steiniche, Torben ^a   Damsgaard, Tine E ^a   Georgsen, Jeanette B ^a   Danielsen, Allan ^a   Bastholt, Lars ^c   Møller, Holger J ^a   Nørgaard, Peter H ^b   Schmidt, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

E cadherin; Epithelial to mesenchymal transition; Macrophages; MelanA; Melanoma; Spindle cell

Indexed keywords

CD163 ANTIGEN; MELAN A; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MLANA PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CELL CLONE; CELL STRUCTURE; COHORT ANALYSIS; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; INFLAMMATION; MACROPHAGE; MAJOR CLINICAL STUDY; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SPINDLE CELL; TUMOR ASSOCIATED LEUKOCYTE; CHEMISTRY; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR MICROENVIRONMENT;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS, TUMOR; CADHERINS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGES; MART-1 ANTIGEN; MELANOMA; PHENOTYPE; RECEPTORS, CELL SURFACE; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84924957373     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000138     Document Type: Article

References (34)

1. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelialmesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009; 119:1438-1449.
2. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995; 154:8-20.
3. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420-1428.
4. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009; 119:1417-1419.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
6. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9:239-252.
7. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124:263-266.
8. Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 2012; 12:35.
9. Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, Xie P, Ding JL. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 2013; 93:844-854.
10. Bønnelykke-Behrndtz ML, Schmidt H, Christensen IJ, Damsgaard TE, Møller HJ, Bastholt L, et al. Prognostic stratification of ulcerated melanoma: not only the extent matters. Am J Clin Pathol 2014; 142:845-856.
11. Hofbauer GF, Kamarashev J, Geertsen R, Böni R, Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res 1998; 8:337-343.
12. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999; 17:2562-2571.
13. Murer K, Urosevic M, Willers J, Selvam P, Laine E, Burg G, Dummer R. Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients. Melanoma Res 2004; 14:257-262.
14. Berset M, Cerottini JP, Guggisberg D, Romero P, Burri F, Rimoldi D, Panizzon RG. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer 2001; 95:73-77.
15. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183:725-729.
16. Pla P, Moore R, Morali OG, Grille S, Martinozzi S, Delmas V, Larue L. Cadherins in neural crest cell development and transformation. J Cell Physiol 2001; 189:121-132.
17. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 2013; 24:466-480.
18. Alonso SR, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, Pollán M, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 2007; 67:3450-3460.
19. Dou J, He X, Liu Y, Wang Y, Zhao F, Wang X, et al. Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs. Cell Biol Int 2014; 38:452-461.
20. Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 2012; 7:e40378.
21. Jayachandran A, Anaka M, Prithviraj P, Hudson C, McKeown SJ, Lo PH, et al. Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget 2014; 5:5782-5797.
22. Helm O, Held-Feindt J, Grage-Griebenow E, Reiling N, Ungefroren H, Vogel I, et al. Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. Int J Cancer 2014; 135:843-861.
23. Maniecki MB, Etzerodt A, Ulhøi BP, Steiniche T, Borre M, Dyrskjøt L, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer 2012; 131:2320-2331.
24. Corsino PE, Davis BJ, Nørgaard PH, Parker NN, Law M, Dunn W, Law BK. Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. Neoplasia 2008; 10:1240-1252.
25. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705-727.
26. Rongioletti F, Smoller BR. Unusual histological variants of cutaneous malignant melanoma with some clinical and possible prognostic correlations. J Cutan Pathol 2005; 32:589-603.
27. Chen LL, Jaimes N, Barker CA, Busam KJ, Marghoob AA. Desmoplastic melanoma: a review. J Am Acad Dermatol 2013; 68:825-833.
28. Garrido MC, Requena L, Kutzner H, Ortiz P, Pérez-Gómez B, Rodriguez-Peralto JL. Desmoplastic melanoma: expression of epithelial-mesenchymal transition-related proteins. Am J Dermatopathol 2014; 36:238-242.
29. Murali R, Shaw HM, Lai K, McCarthy SW, Quinn MJ, Stretch JR, et al. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer 2010; 116:4130-4138.
30. Scolyer RA, Thompson JF. Desmoplastic melanoma: a heterogeneous entity in which subclassification as 'pure' or 'mixed' may have important prognostic significance. Ann Surg Oncol 2005; 12:197-199.
31. Skelton HG, Maceira J, Smith KJ, McCarthy WF, Lupton GP, Graham JH. HMB45 negative spindle cell malignant melanoma. Am J Dermatopathol 1997; 19:580-584.
32. López-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009; 1 (6-7):303-314.
33. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29:4741-4751.
34. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-715.